Compare Stocks → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:BCDANASDAQ:BVXVOTCMKTS:ENZNNASDAQ:LIFE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$0.66-24.9%$11.13$0.61▼$24.20$820K1.4119,299 shs416,900 shsBCDABioCardia$0.38+0.9%$0.42$0.32▼$2.92$10.20M1.47324,375 shs64,379 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsENZNEnzon Pharmaceuticals$0.08+14.7%$0.08$0.06▼$0.23N/A0.336,131 shs125 shsLIFEaTyr Pharma$1.60-1.2%$1.83$1.08▼$2.70$108.70M1.25504,823 shs287,603 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-94.54%-96.11%-92.97%BCDABioCardia+2.23%+3.21%-8.07%-13.76%-81.39%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%-28.80%ENZNEnzon Pharmaceuticals+7.79%+20.37%+11.43%-11.94%-62.63%LIFEaTyr Pharma-1.22%+0.62%-16.92%+5.19%-24.65%He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABCDABioCardia2.8456 of 5 stars3.35.00.00.02.23.30.0BVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALIFEaTyr Pharma2.0568 of 5 stars3.43.00.00.03.21.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/ABCDABioCardia2.50Moderate Buy$4.00954.02% UpsideBVXVBiondVax PharmaceuticalsN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/ALIFEaTyr Pharma2.75Moderate Buy$23.671,379.17% UpsideCurrent Analyst RatingsLatest ENZN, LIFE, ACOR, BVXV, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.01$33.05 per share0.02($127.17) per share-0.01BCDABioCardia$480K21.24N/AN/A($0.07) per share-5.42BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/AENZNEnzon Pharmaceuticals$30KN/AN/AN/AN/AN/ALIFEaTyr Pharma$350K310.58N/AN/A$1.54 per share1.04Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/A∞N/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)BCDABioCardia-$11.57M-$0.55N/AN/AN/A-2,425.79%-3,638.68%-228.55%5/8/2024 (Estimated)BVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/AENZNEnzon Pharmaceuticals$1.37M$0.017.80∞N/AN/A46.47%2.92%N/ALIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)Latest ENZN, LIFE, ACOR, BVXV, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023BCDABioCardia-$0.11-$0.09+$0.02-$0.09$0.20 million$0.01 million3/20/2024Q4 2023ENZNEnzon PharmaceuticalsN/A$0.01+$0.01$0.01N/AN/A3/14/2024Q4 2023LIFEaTyr Pharma-$0.23-$0.25-$0.02-$0.25N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26BCDABioCardiaN/A0.400.40BVXVBiondVax PharmaceuticalsN/A4.124.12ENZNEnzon PharmaceuticalsN/A27.6227.62LIFEaTyr Pharma0.026.276.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%BCDABioCardia20.57%BVXVBiondVax Pharmaceuticals11.83%ENZNEnzon PharmaceuticalsN/ALIFEaTyr Pharma61.72%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%BCDABioCardia23.90%BVXVBiondVax Pharmaceuticals6.03%ENZNEnzon Pharmaceuticals0.27%LIFEaTyr Pharma3.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataBCDABioCardia1626.87 million20.45 millionOptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableENZNEnzon PharmaceuticalsN/AN/AN/ANot OptionableLIFEaTyr Pharma5667.94 million65.43 millionOptionableENZN, LIFE, ACOR, BVXV, and BCDA HeadlinesSourceHeadlineaTyr Pharma Insiders Placed Bullish Bets Worth US$514.6kfinance.yahoo.com - April 21 at 3:56 PMAtal Incubation Centre - Centre for Cellular and Molecular Biology signs agreement with Thermo Fisher Scientific to advance innovation in Indiamsn.com - April 17 at 5:09 PMaTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.54americanbankingnews.com - April 17 at 3:00 AMaTyr Pharma, Inc. (NASDAQ:LIFE) Shares Sold by Stonepine Capital Management LLCmarketbeat.com - April 9 at 9:43 PMaTyr Pharma to Participate in April Investor Conferencesfinance.yahoo.com - April 1 at 8:08 AMaTyr Pharma to Participate in April Investor Conferencesglobenewswire.com - April 1 at 8:00 AMShort Interest in aTyr Pharma, Inc. (NASDAQ:LIFE) Rises By 167.4%marketbeat.com - March 28 at 2:55 PM3 Penny Stocks That Could Be Multibaggers in the Making: March Editioninvestorplace.com - March 26 at 2:19 PM3 Best Stocks to Buy Now, 3/18/2024, According to Top Analystsmsn.com - March 18 at 1:04 PMaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Updatefinanznachrichten.de - March 17 at 8:32 AMRecap: aTyr Pharma Q4 Earningsbenzinga.com - March 16 at 10:33 AMaTyr Pharma Full Year 2023 Earnings: Revenues Disappointfinance.yahoo.com - March 16 at 10:33 AMBuy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial Footingmarkets.businessinsider.com - March 15 at 1:55 PMaTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progressfinance.yahoo.com - March 15 at 1:55 PMQ4 2023 aTyr Pharma Inc Earnings Callfinance.yahoo.com - March 15 at 1:55 PMaTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 15 at 1:55 PMLIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023investorplace.com - March 14 at 10:04 PMAtyr Pharma: Q4 Earnings Snapshotwashingtonpost.com - March 14 at 6:49 PMaTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Updateglobenewswire.com - March 14 at 4:00 PMOptions Volatility and Implied Earnings Moves Today, March 14, 2024msn.com - March 14 at 1:49 PMaTyr Pharma's Earnings Outlookbenzinga.com - March 13 at 7:52 PMAlnylam embarks on road trip-themed campaign to drive earlier diagnosis of hereditary ATTR amyloidosisfiercepharma.com - March 13 at 1:46 PMaTyr Pharma is about to announce earnings — here's what Wall Street expectsmarkets.businessinsider.com - March 13 at 1:46 PMaTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Resultsglobenewswire.com - February 28 at 8:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCharles Schwab Fortifies its Uptrend on EPS Beat April 23, 2024 10:15 AMView Charles Schwab Fortifies its Uptrend on EPS Beat Blackstone’s $10 Billion Bet on Property Prices Going UpApril 11, 2024 7:30 AMView Blackstone’s $10 Billion Bet on Property Prices Going UpAll Headlines Company DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.BioCardiaNASDAQ:BCDABioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.BiondVax PharmaceuticalsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Enzon PharmaceuticalsOTCMKTS:ENZNEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.